Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel shows promise for eczema relief

NCT ID NCT06024499

Symptom relief Sponsor: Shaperon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a gel called HY209 on 210 adults with mild to moderate atopic dermatitis (eczema). The study compared different strengths of the gel to a placebo to see if it could reduce skin redness, itching, and rash. Results will show whether the gel is safe and effective enough to move to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HY209 gel (0.5%, 1%, 2%, or 4%)
What this could lead to
If successful, this gel could offer a new topical option to ease eczema symptoms like redness and itching.
What could go wrong
This is an early-phase trial with only 210 people. The gel may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

210 people

The number who actually took part.

Started

Mar 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female subjects aged 18 or older * Subjects who have a history of AD at least 6 months ago from screening and have been clinically stable for ≥ 1 month * Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist * Subjects who have a minimum of 5% and a maximum of 30% of total body surface area (BSA) affected by AD at screening and baseline visits * Subjects with vIGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visit * Subjects should be a literate person who can read the participant information sheet and consent form/questionnaire and understand the language of the participation Key Exclusion Criteria: * Subjects who have unstable AD (i.e., remaining clinical stable less than 6 months) or any consistent requirement for any potency topical corticosteroids * Subjects who have topical treatment with corticosteroids within 2 weeks prior to baseline visit or other topical treatments of the AD area at screening (moisturizers/emollients are allowed) * Subjects who had systemic treatment with corticosteroids or cyclosporine or other immunosuppressive treatments within 4 weeks prior to baseline visit * Subjects who had dupilumab or any other biologics within 6 months prior to baseline visit * Subjects who take any systemic anti-infective or antibiotic treatments within 1 week prior to baseline visit * Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks prior to screening * Subjects who have active malignancy or history of cancer in 5 years prior to screening, except for treated cautions basal cell carcinoma and in situ cervical cancer * Subjects who have any other skin diseases that would affect the ability to assess the AD * Subjects who are taking any other concomitant drug that, in the opinion of the PI, may cause interference with the treatment * Subjects who participated in another drug or device trial within 4 weeks prior to screening...etc

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Atopic dermatitis (eczema) Atopic dermatitis of scalp

Contacts and locations

Locations

  • Cahaba Dermatology Skin Health Center

    Birmingham, Alabama, 35244, United States

  • Continental Clinical Solutions, LLC

    Towson, Maryland, 21204, United States

  • Gachon University Gil Medical Center

    Seoul, South Korea

  • L.A. Universal Research Center, Inc.

    Los Angeles, California, 90057, United States

  • RAOOF MD Dermatology

    Encino, California, 16133, United States

  • Revival Research Institute, LLC

    Southfield, Michigan, 19505, United States

  • Sadick Dermatology

    New York, New York, 10075, United States

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Zenith Research Inc.

    Los Angeles, California, 90212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.